NBC Securities Inc. Acquires 4,201 Shares of Encompass Health Co. (NYSE:EHC)

NBC Securities Inc. increased its stake in Encompass Health Co. (NYSE:EHC - Free Report) by 140,033.3% during the first quarter, according to its most recent filing with the SEC. The fund owned 4,204 shares of the company's stock after buying an additional 4,201 shares during the quarter. NBC Securities Inc.'s holdings in Encompass Health were worth $425,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EHC. Colonial Trust Co SC purchased a new stake in Encompass Health during the fourth quarter valued at about $29,000. Transce3nd LLC purchased a new stake in Encompass Health during the fourth quarter valued at about $40,000. CBIZ Investment Advisory Services LLC lifted its holdings in Encompass Health by 38.7% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock valued at $42,000 after purchasing an additional 127 shares during the last quarter. V Square Quantitative Management LLC lifted its holdings in Encompass Health by 43.8% during the fourth quarter. V Square Quantitative Management LLC now owns 581 shares of the company's stock valued at $54,000 after purchasing an additional 177 shares during the last quarter. Finally, Signaturefd LLC lifted its holdings in Encompass Health by 21.6% during the fourth quarter. Signaturefd LLC now owns 704 shares of the company's stock valued at $65,000 after purchasing an additional 125 shares during the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Price Performance

Shares of EHC stock traded up $0.28 during trading on Friday, hitting $121.57. The company had a trading volume of 406,135 shares, compared to its average volume of 700,184. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The stock's 50-day moving average is $111.55 and its two-hundred day moving average is $102.58. The stock has a market capitalization of $12.25 billion, a price-to-earnings ratio of 27.26, a price-to-earnings-growth ratio of 2.31 and a beta of 0.89. Encompass Health Co. has a 52 week low of $82.74 and a 52 week high of $123.13.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.18. The company had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Encompass Health's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.12 earnings per share. As a group, analysts predict that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date is Tuesday, July 1st. Encompass Health's payout ratio is 14.05%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on EHC shares. UBS Group upped their price objective on shares of Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday, April 28th. Royal Bank of Canada upped their price target on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Stephens reiterated an "overweight" rating and set a $135.00 price target on shares of Encompass Health in a research report on Thursday. Truist Financial reiterated a "buy" rating and set a $135.00 price target (up from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. Finally, William Blair reiterated an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $127.00.

Insider Buying and Selling

In other Encompass Health news, CEO Mark J. Tarr sold 118,384 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the completion of the transaction, the chief executive officer now owns 527,070 shares in the company, valued at approximately $64,054,817.10. This represents a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the transaction, the insider now owns 11,958 shares of the company's stock, valued at approximately $1,394,422.38. This trade represents a 26.35% decrease in their position. The disclosure for this sale can be found here. Insiders sold 132,663 shares of company stock valued at $16,034,082 over the last quarter. 2.10% of the stock is owned by company insiders.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.